All products are for research use only. Not for human consumption.
The evolution of incretin-based research peptides is one of the clearest examples of iterative pharmacology in modern metabolic science. In just over a decade, researchers moved from single-receptor GLP-1 agonists to dual GIP/GLP-1 compounds and finally to triple-receptor triagonists. Each generation built directly on the limitations and unanswered questions of the previous one.
This article walks through the three landmark molecules — semaglutide, tirzepatide, and retatrutide — focusing on receptor targets, half-lives, and the published trial data that defines them. All compounds discussed are intended for research use only.
Semaglutide is a selective GLP-1 receptor agonist with 94% structural homology to native human GLP-1. Two key modifications — an Aib substitution at position 8 and a C18 fatty diacid side chain — confer resistance to DPP-4 degradation and promote albumin binding.
The result is a half-life of approximately 165 hours (about 7 days), which made once-weekly dosing schedules feasible in clinical research. This was a major shift from earlier GLP-1 analogs with half-lives measured in hours.
The STEP and SUSTAIN trial programs, published across multiple papers in the New England Journal of Medicine, established semaglutide as the reference compound for incretin-based research. The SELECT cardiovascular outcomes trial added cardiovascular endpoint data to a growing literature.
Tirzepatide engages both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Structurally based on the GIP backbone with modifications enabling GLP-1 cross-reactivity, the molecule shows roughly 5-fold higher affinity for GIP than GLP-1.
Tirzepatide's half-life is approximately 5 days, again supporting once-weekly research dosing. Like semaglutide, it uses fatty acid conjugation to extend albumin-mediated retention.
The SURPASS and SURMOUNT programs documented metabolic effects in research populations that exceeded those reported with selective GLP-1 agonism. Notably, GIP receptor engagement appears to contribute to tolerability characteristics that distinguish it mechanistically from semaglutide.
Retatrutide adds a third receptor — glucagon — to the dual-agonist template. Triagonism introduces a fundamentally different metabolic component because glucagon receptor activation is associated with increased hepatic energy expenditure and lipolysis.
Retatrutide's reported half-life is approximately 6 days, again compatible with weekly research dosing schedules.
Phase 2 data published in the New England Journal of Medicine in 2023 reported the largest metabolic effects observed to date in incretin research at the highest dose levels investigated. Phase 3 work is ongoing.
The progression from one to three receptors is not simply additive. Each receptor system activates distinct signaling cascades, and researchers studying these compounds are essentially comparing fundamentally different pharmacological profiles. GLP-1 engagement promotes glucose-dependent insulin secretion. GIP engagement modulates beta-cell responsiveness and adipose metabolism. Glucagon engagement increases hepatic energy turnover.
Each compound serves a slightly different role in modern preclinical research. Semaglutide remains the comparator molecule in studies examining single-receptor pharmacology. Tirzepatide is central to research questions about complementary receptor engagement. Retatrutide is the focus of work investigating glucagon's role in energy balance alongside incretin signaling.
Although semaglutide and tirzepatide have received approvals in clinical contexts in some jurisdictions, the products supplied through research peptide channels are strictly for laboratory research use only. Retatrutide is investigational and has not received any regulatory approval. None of the compounds discussed should be administered to humans outside of authorized clinical trials.
The number and identity of incretin receptors they engage. Semaglutide is a selective GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist.
Yes — all three compounds support weekly dosing in research settings, with half-lives in the 5–7 day range. This is achieved through fatty acid conjugation that promotes albumin binding.
The forms supplied to research labs are strictly for laboratory research use only. Even where clinical approvals exist for related products, research-grade peptides are not intended for human consumption.
Disclaimer: This article is provided for educational and informational purposes only. It does not constitute medical advice. All products referenced are intended strictly for laboratory research use only and are not approved for human consumption.
52 compounds. 99%+ purity. Certificate of Analysis included with every order.